In a matched study of 248 lung transplant recipients, letermovir use after valganciclovir intolerance was associated with hematologic recovery and no significant increase in CMV reactivation versus valganciclovir. Abstract Background Lung transplant recipients are at high risk for severe cytomegalovirus (CMV) disease. Off-label use of letermovir...

Transplant Infectious Disease, EarlyView.

One-third of the study population and two-thirds of lung recipients had recurrent post-prophylaxis CMV DNAemia. Recurrent DNAemia was not associated with 5-year mortality. Abstract Background Cytomegalovirus (CMV) mismatched, donor IgG-positive/recipient IgG-negative, solid organ transplant recipients (SOTRs) are at high risk of CMV invasive...

The utilization of CMV CD4+ cellular immunity to guide duration of CMV prophylaxis in high-risk patients did not lead to increased risk of clinically significant CMV viremia in kidney and/or pancreas transplant recipients. Abstract Background Valganciclovir prophylaxis against cytomegalovirus (CMV) is recommended for solid organ transplant...

In this single-center, pilot study, we prospectively evaluated cytomegalovirus-specific T-cell-mediated immunity (CMV-CMI) in allogeneic hematopoietic cell transplantation recipients using a commercially available US flow cytometry assay. CMV-CMI recovery was slower in haploidentical and mismatched donors receiving post-transplant cyclophosphamide...

When comparing various antiretroviral and induction combinations in 77 HIV infected kidney transplant recipients, the use of rabbit anti-thymocyte globulin for induction and protease inhibitor sparing antiretrovirals resulted in a trend toward lower rejection and improved graft survival. Abstract Purpose Kidney transplantation has a survival...